Literature DB >> 11230396

Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0.

P Swanson1, V Soriano, S G Devare, J Hackett.   

Abstract

The performance of the LCx HIV RNA Quantitative (LCx HIV), AMPLICOR HIV-1 MONITOR version 1.5 (MONITOR v1.5), and Quantiplex HIV-1 RNA version 3.0 (bDNA v3.0) viral load assays was evaluated with 39 viral isolates (3 A, 7 B, 6 C, 4 D, 8 E, 4 F, 1 G, 4 mosaic, and 2 group O). Quantitation across the assay dynamic ranges was assessed using serial fivefold dilutions of the viruses. In addition, sequences of gag-encoded p24 (gag p24), pol-encoded integrase, and env-encoded gp41 were analyzed to assign group and subtype and to assess nucleotide mismatches at primer and probe binding sites. For group M isolates, quantification was highly correlated among all three assays. In contrast, only the LCx HIV assay reliably quantified group O isolates. The bDNA v3.0 assay detected but consistently underquantified group O viruses, whereas the MONITOR v1.5 test failed to detect group O viruses. Analysis of target regions revealed fewer primer or probe mismatches in the LCx HIV assay than in the MONITOR v1.5 test. Consistent with the high level of nucleotide conservation is the ability of the LCx HIV assay to quantify efficiently human immunodeficiency virus type 1 group M and the genetically diverse group O.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230396      PMCID: PMC87842          DOI: 10.1128/JCM.39.3.862-870.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  42 in total

1.  First case of HIV-1 group O infection in Spain.

Authors:  V Soriano; M Gutiérrez; G García-Lerma; O Aguilera; A Mas; R Bravo; M L Pérez-Labad; M Baquero; J González-Lahoz
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

Review 2.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

3.  First case of HIV-1 subtype 0 infection in Germany.

Authors:  H Hampl; D Sawitzky; M Stöffler-Meilicke; A Groh; M Schmitt; J Eberle; L Gürtler
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

4.  HIV-1 group O virus identified for the first time in the United States.

Authors:  M A Rayfield; P Sullivan; C I Bandea; L Britvan; R A Otten; C P Pau; D Pieniazek; S Subbarao; P Simon; C A Schable; A C Wright; J Ward; G Schochetman
Journal:  Emerg Infect Dis       Date:  1996 Jul-Sep       Impact factor: 6.883

5.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

6.  HIV type 1 diversity in northern Paris, France.

Authors:  F Simon; I Loussert-Ajaka; F Damond; S Saragosti; F Barin; F Brun-Vézinet
Journal:  AIDS Res Hum Retroviruses       Date:  1996-10-10       Impact factor: 2.205

7.  Genetic diversity and HIV detection by polymerase chain reaction.

Authors:  I Loussert-Ajaka; D Descamps; F Simon; F Brun-Vézinet; M Ekwalanga; S Saragosti
Journal:  Lancet       Date:  1995-09-30       Impact factor: 79.321

8.  Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples.

Authors:  H C Highbarger; W G Alvord; M K Jiang; A S Shah; J A Metcalf; H C Lane; R L Dewar
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

9.  An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D Kern; M Collins; T Fultz; J Detmer; S Hamren; J J Peterkin; P Sheridan; M Urdea; R White; T Yeghiazarian; J Todd
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  11 in total

1.  Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02).

Authors:  Alessandra Amendola; Licia Bordi; Claudio Angeletti; Enrico Girardi; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.

Authors:  Claire Ham; Priya Srinivasan; Rigmor Thorstensson; Ernst Verschoor; Zahra Fagrouche; Leonardo Sernicola; Artur Ramos; Fausto Titti; Neil Almond; Neil Berry
Journal:  J Clin Microbiol       Date:  2010-04-28       Impact factor: 5.948

3.  Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil.

Authors:  Jan Felix Drexler; Luciano Kleber de Souza Luna; Celia Pedroso; Diana Brasil Pedral-Sampaio; Artur T L Queiroz; Carlos Brites; Eduardo M Netto; Christian Drosten
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

4.  Comparison of the Abbott m2000 HIV-1 Real-Time and Roche AMPLICOR Monitor v1.5 HIV-1 assays on plasma specimens from Rakai, Uganda.

Authors:  I Ssebugenyi; A Kizza; B Mpoza; G Aluma; I Boaz; K Newell; O Laeyendecker; J P Shott; D Serwadda; S J Reynolds
Journal:  Int J STD AIDS       Date:  2011-07       Impact factor: 1.359

5.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

6.  Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV.

Authors:  Jérôme Legoff; Hicham Bouhlal; Gérard Grésenguet; Helen Weiss; Nzambi Khonde; Hakim Hocini; Nathalie Désiré; Ali Si-Mohamed; Jean de Dieu Longo; Cécile Chemin; Eric Frost; Jacques Pépin; Jean-Elie Malkin; Philippe Mayaud; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Evaluation of automated sample preparation and quantitative PCR LCx assay for determination of human immunodeficiency virus type 1 RNA.

Authors:  Zsofia Muller; Evelyn Stelzl; Michael Bozic; Josef Haas; Egon Marth; Harald H Kessler
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates.

Authors:  Andre J Marozsan; Erika Fraundorf; Awet Abraha; Heather Baird; Dawn Moore; Ryan Troyer; Immaculate Nankja; Eric J Arts
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

Authors:  Tonie Cilliers; Jabulani Nhlapo; Mia Coetzer; Dragana Orlovic; Thomas Ketas; William C Olson; John P Moore; Alexandra Trkola; Lynn Morris
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.